nausea; this is a spontaneous report received from a contactable consumer from the regulatory agency. regulatory number: gb-mhra-webcovid-202202150921539870-n55ur. other case identifier(s): gb-mhra-adr 26606359. a 43 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 12feb2022 (batch/lot number: unknown) at the age of 43 years as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "steroid therapy" (unspecified if ongoing), notes: taking regular steroid treatment (e.g. orally or rectally). patient had not had symptoms associated with covid-19 and not had a covid-19 test. patient was not currently breastfeeding. the patient's concomitant medications were not reported. past drug history included: sertralin. vaccination history included: bnt162b2 (dose 1, single), for covid-19 immunisation; bnt162b2 (dose 2, single), for covid-19 immunisation. the following information was reported: nausea (medically significant) with onset 12feb2022, outcome "not recovered", described as "nausea". patient had not tested positive for covid-19 since having the vaccine. patient was not enrolled in clinical trial. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected